These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31061068)

  • 1. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial.
    Gangat N; Marinaccio C; Swords R; Watts JM; Gurbuxani S; Rademaker A; Fought AJ; Frankfurt O; Altman JK; Wen QJ; Farnoud N; Famulare CA; Patel A; Tapia R; Vallapureddy RR; Barath S; Graf A; Handlogten A; Zblewski D; Patnaik MM; Al-Kali A; Dinh YT; Englund Prahl K; Patel S; Nobrega JC; Tejera D; Thomassen A; Gao J; Ji P; Rampal RK; Giles FJ; Tefferi A; Stein B; Crispino JD
    Clin Cancer Res; 2019 Aug; 25(16):4898-4906. PubMed ID: 31061068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
    Wen QJ; Yang Q; Goldenson B; Malinge S; Lasho T; Schneider RK; Breyfogle LJ; Schultz R; Gilles L; Koppikar P; Abdel-Wahab O; Pardanani A; Stein B; Gurbuxani S; Mullally A; Levine RL; Tefferi A; Crispino JD
    Nat Med; 2015 Dec; 21(12):1473-80. PubMed ID: 26569382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin-dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis.
    Wang F; Zhang H; He B; Liu Z; Wu X; Liu Y; Xu X; Gou X; Wang H; Yang Q
    Hematol Oncol; 2023 Aug; 41(3):474-486. PubMed ID: 36422297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next Generation Therapeutics for the Treatment of Myelofibrosis.
    Tremblay D; Mascarenhas J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
    Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
    Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib: a new treatment option for myelofibrosis.
    Ganetsky A
    Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
    Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
    PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
    Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
    Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
    Bucelli C; Cattaneo D; Valli VB; Levati GV; Lonati S; Gianelli U; Iurlo A
    Chemotherapy; 2018; 63(6):340-344. PubMed ID: 30965327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow.
    Nakayama S; Yokote T; Hiraoka N; Akioka T; Nishiwaki U; Miyoshi T; Iwaki K; Fumimoto A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M
    Hum Pathol; 2017 Apr; 62():180-186. PubMed ID: 28159675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?
    Piszczatowski RT; Steidl U
    Clin Cancer Res; 2019 Aug; 25(16):4868-4870. PubMed ID: 31196854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
    Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
    Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
    Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
    Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
    Stein BL; Swords R; Hochhaus A; Giles F
    Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.